Listar Enfermidades endocrinas, nutricionais e metabólicas por autor "López-Muñiz, Andrés"
Mostrando ítems 1-5 de 5
-
Effect of dialysis modality and other prescription factors on peritoneal protein excretion in peritoneal dialysis
Rodríguez-Carmona, Ana; Pérez-Fontán, Miguel; Pértega-Díaz, Sonia; López-Calviño, Beatriz; López-Muñiz, Andrés; García-Falcón, Teresa (Elsevier, 2012-11)[Abstract] Background: There is a deficit of information regarding the factors that influence peritoneal protein excretion (PPE) during PD therapy. In particular, the effects of the modality of PD and other conditions of ... -
Getting the right patient on the right renal replacement therapy
Pérez-Fontán, Miguel; Rodríguez-Carmona, Ana; López-Muñiz, Andrés; García-Falcón, Teresa (Karger, 2012-05)[Abstract] Adequate selection of the modality of renal replacement therapy (RRT), ideally based on well-planned predialysis care, informed decision by the patient and timely initiation of dialysis, is essential to optimize ... -
Peritoneal protein transport during the baseline peritoneal equilibration test is an accurate predictor of the outcome of peritoneal dialysis patients
Pérez-Fontán, Miguel; Rodríguez Carmona, Ana; Barreda, D.; López-Muñiz, Andrés; Blanco-Castro, N.; García Falcón, María Teresa (Karger, 2010)[Abstract] Background: Peritoneal protein excretion (PPE) is a potential marker of the outcome in peritoneal dialysis (PD) patients. Method: Observational study of a cohort of 269 patients starting PD in a single unit. ... -
Peritoneal total protein transport assessed from peritoneal equilibration tests using different dialysate glucose concentrations
Gomes, Ana Marta; Pérez-Fontán, Miguel; Rodríguez-Carmona, Ana; López-Muñiz, Andrés; Fernández-Villar, Marcos; Peteiro-Cartelle, Javier; García-Falcón, Teresa (SAGE, 2010-09)[Abstract] Background: The peritoneal equilibration test (PET) permits assessment of peritoneal protein transport, but this potential marker of outcome in peritoneal dialysis (PD) patients lacks adequate standardization. ... -
Serum levels of the adipomyokine irisin in patients with chronic kidney disease
Rodríguez-Carmona, Ana; Pérez-Fontán, Miguel; Sangiao-Alvarellos, Susana; García Falcón, María Teresa; Pena-Bello, Lara; López-Muñiz, Andrés; Cordido, Fernando (Elsevier, 2016-12-14)[Abstract] Background. Irisin is an adipomyokine with claimed anti-obesity and anti-diabetic effects. This hormone has been insufficiently studied in patients with advanced chronic kidney disease (CKD). Objective. To ...